[go: up one dir, main page]

SE9002550D0 - heparin fragments - Google Patents

heparin fragments

Info

Publication number
SE9002550D0
SE9002550D0 SE9002550A SE9002550A SE9002550D0 SE 9002550 D0 SE9002550 D0 SE 9002550D0 SE 9002550 A SE9002550 A SE 9002550A SE 9002550 A SE9002550 A SE 9002550A SE 9002550 D0 SE9002550 D0 SE 9002550D0
Authority
SE
Sweden
Prior art keywords
heparin
regardless
activity
relates
bleeding time
Prior art date
Application number
SE9002550A
Other languages
Swedish (sv)
Inventor
H-P T Ekre
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE9002550A priority Critical patent/SE9002550D0/en
Publication of SE9002550D0 publication Critical patent/SE9002550D0/en
Priority to PCT/SE1991/000502 priority patent/WO1992002232A1/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

This invention relates to the use of heparin fragment showing complement inhibition activity and reduced bleeding time when compared to heparin regardless of anticoagulant activity for the manufacturing of medicaments for treating pathological inflammations as well as the method for treatment of pathological inflammations by administration of the heparin fragment. The invention also relates to a method for finding heparin fragments with high therapeutical value by choosing those with short bleeding time and high complement inhibition activity regardless of anticoagulant activity. Another aspect of the invention is the heparin fragment showing complement inhibition activity and reduced bleeding time when compared to heparin regardless of anticoagulant activity and pharmaceutical compositions containing them. The invention also relates to the process for the preparation of heparin fragments.
SE9002550A 1990-08-01 1990-08-01 heparin fragments SE9002550D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE9002550A SE9002550D0 (en) 1990-08-01 1990-08-01 heparin fragments
PCT/SE1991/000502 WO1992002232A1 (en) 1990-08-01 1991-07-19 Heparin fragment showing complement inhibition activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002550A SE9002550D0 (en) 1990-08-01 1990-08-01 heparin fragments

Publications (1)

Publication Number Publication Date
SE9002550D0 true SE9002550D0 (en) 1990-08-01

Family

ID=20380076

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9002550A SE9002550D0 (en) 1990-08-01 1990-08-01 heparin fragments

Country Status (2)

Country Link
SE (1) SE9002550D0 (en)
WO (1) WO1992002232A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
EP0735050B1 (en) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US6569840B1 (en) 1997-11-20 2003-05-27 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US9351992B2 (en) 2007-11-02 2016-05-31 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
CN102985443B (en) 2010-04-16 2017-05-10 动量制药公司 Tissue targeting
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
DK2794665T3 (en) * 2011-12-19 2018-01-29 Dilafor Ab NON-ANTICOAGULATIVE GLYCOSAMINOGLYCANES COMPREHENSIVE DISACCHARID REPEATING UNIT AND MEDICAL USE THEREOF
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CA2910837A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation

Also Published As

Publication number Publication date
WO1992002232A1 (en) 1992-02-20

Similar Documents

Publication Publication Date Title
SE9002550D0 (en) heparin fragments
RU93054168A (en) DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS
PT88930A (en) METHOD FOR THE PREPARATION OF NEW ANALYSES OF NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FI833605A0 (en) NY ORAL MOPIDAMOL PRODUCT
DE3268075D1 (en) Preparation for treating outer skin wounds and process for manufacturing said preparation
PT82724B (en) PROCESS FOR THE PREPARATION OF DIFLUORO DERIVATIVES CETONA-PEPTIDEES AND A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
BR9205640A (en) Apolipoprotein dimer ai-milano, pharmacological composition, process of preparation of the dimer, use of this in the preparation of medicines and process for the treatment of atherosclerosis and cardiovascular diseases
BR9813373A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient
UA45942A (en) 1,3-OXATHYOLANE, ITS DERIVATIVES, METHOD (OPTIONS) OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
DK0396184T3 (en) Use of ketoconazole and a retinoid for the treatment of acne vulgaris
ATE215967T1 (en) ANTICOAGULATION COMPOUND ISOLATED FROM URINE
BR9910179A (en) Compound, pharmaceutical composition, use of a compound, and process for treating a disease or condition mediated by factor xa in a warm-blooded animal
DK227282A (en) ANTI-THROMBOTIC BASED ON POLYSACCHARIDES PROCEDURE FOR ITS MANUFACTURING AND PHARMACEUTICAL PRODUCTS
NO872675D0 (en) Means for inhibiting the disposal of transplanted organs
SE8505488L (en) ISOSILYBIN-FREE SILIBININ
EP0333243A3 (en) Sulphated k5 antigen and sulphated k5 antigen fragments
IT8722544A0 (en) EPARAN SULFATE CHARACTERIZED BY HIGH ANTITHROMBOTIC ACTIVITY HIGH BIOAVAILABILITY ABSENCE OF ANTICOAGULANT ACTIVITY; ITS EXTRACTION PROCESS FROM ORGANS AND TISSUES AND RELATED PHARMACEUTICAL COMPOSITIONS
HUT53291A (en) Process for production of medical compositions applicable for treatment of inflammation of diarthrosis
ATE187648T1 (en) COMPOSITIONS CONTAINING LIPOPROTEIN ASSOCIATED COAGULATION INHIBITOR (LACI) FOR PRODUCING A MEDICATION FOR THE TREATMENT OF ACUTE OR CHRONIC INFLAMMATION
IT8721115A0 (en) PHYTO-PREPARATION FOR THE TREATMENT OF SKIN DISEASES.
ATE119781T1 (en) ANTICOAGULANT PREPARATION.
ES478686A1 (en) Antithrombotic 2-(gamma-(1-piperidinyl)propyl)1,2-benzisothiazol 3-one, its pharmaceutically acceptable acid addition salts, their preparation and their compositions.
DK277387A (en) THERAPEUTIC TOPICAL COMPOSITION AGAINST A HYPERPROLIFIING EPITHAL DISEASE
BR9908387A (en) Process for the preparation of 5-imino-13-deoxyanthracycline derivatives, respective compounds and pharmaceutical composition and method of treating cancer, autoimmune diseases or immunodeficiency disorders
SU1169655A1 (en) Method of treatment of thrombolytic diseases of the artery of the extremities